Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Summary
To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate the Efficacy and Safety of Oral SSS17 Capsules in the Treatment of Anemia Following Total Hip or Knee Arthroplasty
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-07
Completion Date
2026-04
Last Updated
2025-06-11
Healthy Volunteers
No
Interventions
SSS17 Capsule (6 Dose Levels)
Arm1 : This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly
Placebo Drug
Arm2:placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).
Locations (1)
Peking University People's Hospital
Beijing, China